AGER-peptides and use thereof

US9291621B2 · kind B2 · utility

Assignee

• Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

• Alfred Hahn · Erlangen, DE
• Ralf Loebbert · Speyer, DE
• Nicole Teusch · Uerdingen, DE
• Achim Möller · Bad Kötzting, DE
• Ulrich Ebert · Mannheim, DE
• Martin Schmidt · Frankfurt am Main, DE

Key dates

• Filing date: Jan 18, 2006
• Grant date: Mar 22, 2016
• Expiry date: May 12, 2031

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor multimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER.